0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Letter to the Editor   |    
Differing Tolerability Profiles Among Atypical Antipsychotics
JONATHAN S.E. HELLEWELL, M.B., CH.B., M.SC., M.R.C.PSYCH.; PETER M. HADDAD, M.D., M.B., CH.B., M.SC., M.R.C.PSYCH.
Am J Psychiatry 2001;158:501-501. doi:10.1176/appi.ajp.158.3.501

To the Editor: We read with interest the article by David B. Allison, Ph.D., et al. (1) in which they reported weight gain over 10 weeks’ treatment with a number of antipsychotics. Unfortunately, data for the atypical antipsychotic quetiapine were not included. Jones et al. (2) reported at the recent Biennial Winter Workshop on Schizophrenia a mean weight gain of 2.16 kg (4.75 lb) in patients with schizophrenia and other psychoses after 10 weeks’ treatment with quetiapine at a mean dose of 480 mg/day. After 6 months’ treatment, the mean weight gain was 1.85 kg (4.07 lb) in a sample of 556 patients, whereas after 1 year, the increase was 2.77 kg (6.09 lb) (N=360).

This suggests that with quetiapine, weight gain with short-term treatment does not necessarily presage continued weight gain over the longer term. Concomitant antipsychotic medication was, however, permitted during the open-label extension phase of these studies, thus making difficult any definitive attribution of weight gain to any particular agent. However, Brecher and Melvin (3) recently reported that in a separate population in whom quetiapine was used as monotherapy, a median weight gain of only 1 kg was seen after treatment periods of between 53 and 78 weeks.

Dr. Allison and colleagues highlighted clozapine and olanzapine as being associated with more weight gain than other atypicals and suggested that they may, as a result, also contribute to the development of type II diabetes (4, 5). It is intriguing that Reinstein et al. (6) reported on a case series in which quetiapine appeared to normalize weight and diabetes control in patients who had previously both gained weight and developed diabetes while taking clozapine.

Although the atypical antipsychotics appear to have a more favorable side effect profile than do the conventional agents, their differing tolerability relative to one another (for example, in extrapyramidal side effects, prolactin, and weight effects) also should be considered when selecting treatments for patients with schizophrenia and other related disorders.

The authors have received research grants, sponsorship to attend conferences, consultancy payments, and lecture fees from AstraZeneca and other companies involved in the development of antipsychotics.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–  1696
 
Jones AM, Rak IW, Raniwalla J, Phung D, Melvin K: Weight changes in patients treated with Seroquel (quetiapine) (abstract). Schizophr Res  2000; 41:206
 
Brecher M, Melvin K: Long-term effects of quetiapine monotherapy on weight in patients with schizophrenia, in Abstracts of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN, ACNP, 2000, p 351
 
Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE: Clozapine and associated diabetes mellitus. J Clin Psychiatry  1997; 58:108–111
[PubMed]
[CrossRef]
 
Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry  1998; 44:778–783
[PubMed]
[CrossRef]
 
Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest  1999; 18:99–104
[CrossRef]
 
+

References

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–  1696
 
Jones AM, Rak IW, Raniwalla J, Phung D, Melvin K: Weight changes in patients treated with Seroquel (quetiapine) (abstract). Schizophr Res  2000; 41:206
 
Brecher M, Melvin K: Long-term effects of quetiapine monotherapy on weight in patients with schizophrenia, in Abstracts of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN, ACNP, 2000, p 351
 
Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE: Clozapine and associated diabetes mellitus. J Clin Psychiatry  1997; 58:108–111
[PubMed]
[CrossRef]
 
Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry  1998; 44:778–783
[PubMed]
[CrossRef]
 
Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest  1999; 18:99–104
[CrossRef]
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Topic Collections
Psychiatric News
PubMed Articles